CAR immune cells: design principles, resistance and the next generation
L Labanieh, CL Mackall - Nature, 2023 - nature.com
The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
Interleukins in cancer: from biology to therapy
Interleukins and associated cytokines serve as the means of communication for innate and
adaptive immune cells as well as non-immune cells and tissues. Thus, interleukins have a …
adaptive immune cells as well as non-immune cells and tissues. Thus, interleukins have a …
Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL
J Zhang, Y Hu, J Yang, W Li, M Zhang, Q Wang… - Nature, 2022 - nature.com
Recently, chimeric antigen receptor (CAR)-T cell therapy has shown great promise in
treating haematological malignancies,,,,,–. However, CAR-T cell therapy currently has …
treating haematological malignancies,,,,,–. However, CAR-T cell therapy currently has …
Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing
A Dimitri, F Herbst, JA Fraietta - Molecular cancer, 2022 - Springer
Abstract Chimeric Antigen Receptor (CAR) T-cells represent a breakthrough in personalized
cancer therapy. In this strategy, synthetic receptors comprised of antigen recognition …
cancer therapy. In this strategy, synthetic receptors comprised of antigen recognition …
Engineering strategies to enhance oncolytic viruses in cancer immunotherapy
Y Tian, D Xie, L Yang - Signal transduction and targeted therapy, 2022 - nature.com
Oncolytic viruses (OVs) are emerging as potentially useful platforms in treatment methods for
patients with tumors. They preferentially target and kill tumor cells, leaving healthy cells …
patients with tumors. They preferentially target and kill tumor cells, leaving healthy cells …
Enhanced safety and efficacy of protease-regulated CAR-T cell receptors
Regulatable CAR platforms could circumvent toxicities associated with CAR-T therapy, but
existing systems have shortcomings including leakiness and attenuated activity. Here, we …
existing systems have shortcomings including leakiness and attenuated activity. Here, we …
[HTML][HTML] Engineering CAR-T cells for next-generation cancer therapy
M Hong, JD Clubb, YY Chen - Cancer cell, 2020 - cell.com
T cells engineered to express chimeric antigen receptors (CARs) with tumor specificity have
shown remarkable success in treating patients with hematologic malignancies and …
shown remarkable success in treating patients with hematologic malignancies and …
Synthetic cytokine circuits that drive T cells into immune-excluded tumors
Chimeric antigen receptor (CAR) T cells are ineffective against solid tumors with
immunosuppressive microenvironments. To overcome suppression, we engineered circuits …
immunosuppressive microenvironments. To overcome suppression, we engineered circuits …
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
S Rafiq, CS Hackett, RJ Brentjens - Nature reviews Clinical oncology, 2020 - nature.com
T cells genetically engineered to express chimeric antigen receptors (CARs) have proven—
and impressive—therapeutic activity in patients with certain subtypes of B cell leukaemia or …
and impressive—therapeutic activity in patients with certain subtypes of B cell leukaemia or …
Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors
Adoptive cell therapy (ACT) has proven to be highly effective in treating blood cancers, but
traditional approaches to ACT are poorly effective in treating solid tumors observed …
traditional approaches to ACT are poorly effective in treating solid tumors observed …